Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort.
Where this comes from
- Record sourced from PubMed, PMID 42276786.
- Also identified by DOI 10.2967/jnumed.125.271680.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
It is unclear whether the imaging modality used to guide metastasis-directed therapy (MDT) influences outcomes in oligometastatic castration-resistant prostate cancer (omCRPC). <b>Methods:</b> We performed an updated analysis of the PRECISE-MDT cohort, adding 27 patients to the original cohort. MDT guided by prostate-specific membrane antigen (PSMA) PET/CT, choline PET/CT, and conventional imaging was compared in 102 patients with omCRPC. The primary outcomes were biochemical recurrence-free survival and overall survival after adjustment for inverse probability of treatment weighting. <b>Results:</b> MDT was guided by conventional imaging in 20 (19.6%) patients, choline PET/CT in 56 (54.9%) patients, and PSMA PET/CT in 26 (25.5%) patients. PSMA PET/CT guidance yielded longer biochemical recurrence-free survival than did choline PET/CT (median not reached [NR] vs. 11.7 mo, <i>P</i> = 0.031) and conventional imaging (NR vs. 7.1 mo, <i>P</i> = 0.002). Overall survival favored PSMA PET/CT versus conventional imaging (NR vs. 46.0 mo, <i>P</i> = 0.036). <b>Conclusion:</b> PSMA PET/CT guidance was associated with improved clinical outcome, supporting its therapeutic relevance for MDT planning in omCRPC.